Revision as of 01:00, 24 January 2023 editEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers174,373 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper← Previous edit | Revision as of 09:40, 10 August 2023 edit undoCitation bot (talk | contribs)Bots5,458,312 edits Add: s2cid. | Use this bot. Report bugs. | Suggested by Abductive | Category:Anticonvulsant stubs | #UCB_Category 21/39Next edit → | ||
Line 51: | Line 51: | ||
}} | }} | ||
'''SIB-1893''' is a drug used in scientific research which was one of the first compounds developed that acts as a selective ] for the ] subtype ].<ref name="pmid10381773">{{cite journal |vauthors=Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Veliçelebi G, Johnson EC |title=SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5 |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=290 |issue=1 |pages=170–81 |date=July 1999 |pmid=10381773 }}</ref> It has ] and ] effects,<ref name="pmid10854901">{{cite journal |vauthors=Chapman AG, Nanan K, Williams M, Meldrum BS |title=Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893) |journal=Neuropharmacology |volume=39 |issue=9 |pages=1567–74 |date=July 2000 |pmid=10854901 |doi= 10.1016/S0028-3908(99)00242-7}}</ref> and reduces glutamate release.<ref name="pmid14982967">{{cite journal |vauthors=Wang SJ, Sihra TS |title=Noncompetitive metabotropic glutamate5 receptor antagonist (E)-2-methyl-6-styryl-pyridine (SIB1893) depresses glutamate release through inhibition of voltage-dependent Ca2+ entry in rat cerebrocortical nerve terminals (synaptosomes) |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=309 |issue=3 |pages=951–8 |date=June 2004 |pmid=14982967 |doi=10.1124/jpet.103.064881 }}</ref> It has also been found to act as a positive allosteric modulator of ].<ref name="pmid12684257">{{cite journal |vauthors=Mathiesen JM, Svendsen N, Bräuner-Osborne H, Thomsen C, Ramirez MT |title=Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP |journal=] |volume=138 |issue=6 |pages=1026–30 |date=March 2003 |pmid=12684257 |pmc=1573757 |doi=10.1038/sj.bjp.0705159 }}</ref> | '''SIB-1893''' is a drug used in scientific research which was one of the first compounds developed that acts as a selective ] for the ] subtype ].<ref name="pmid10381773">{{cite journal |vauthors=Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Veliçelebi G, Johnson EC |title=SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5 |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=290 |issue=1 |pages=170–81 |date=July 1999 |pmid=10381773 }}</ref> It has ] and ] effects,<ref name="pmid10854901">{{cite journal |vauthors=Chapman AG, Nanan K, Williams M, Meldrum BS |title=Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893) |journal=Neuropharmacology |volume=39 |issue=9 |pages=1567–74 |date=July 2000 |pmid=10854901 |doi= 10.1016/S0028-3908(99)00242-7|s2cid=21528282 }}</ref> and reduces glutamate release.<ref name="pmid14982967">{{cite journal |vauthors=Wang SJ, Sihra TS |title=Noncompetitive metabotropic glutamate5 receptor antagonist (E)-2-methyl-6-styryl-pyridine (SIB1893) depresses glutamate release through inhibition of voltage-dependent Ca2+ entry in rat cerebrocortical nerve terminals (synaptosomes) |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=309 |issue=3 |pages=951–8 |date=June 2004 |pmid=14982967 |doi=10.1124/jpet.103.064881 |s2cid=800526 }}</ref> It has also been found to act as a positive allosteric modulator of ].<ref name="pmid12684257">{{cite journal |vauthors=Mathiesen JM, Svendsen N, Bräuner-Osborne H, Thomsen C, Ramirez MT |title=Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP |journal=] |volume=138 |issue=6 |pages=1026–30 |date=March 2003 |pmid=12684257 |pmc=1573757 |doi=10.1038/sj.bjp.0705159 }}</ref> | ||
==References== | ==References== |
Revision as of 09:40, 10 August 2023
Chemical compound Pharmaceutical compoundIdentifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H13N |
Molar mass | 195.265 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
SIB-1893 is a drug used in scientific research which was one of the first compounds developed that acts as a selective antagonist for the metabotropic glutamate receptor subtype mGluR5. It has anticonvulsant and neuroprotective effects, and reduces glutamate release. It has also been found to act as a positive allosteric modulator of mGluR4.
References
- Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Veliçelebi G, Johnson EC (July 1999). "SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5". The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 170–81. PMID 10381773.
- Chapman AG, Nanan K, Williams M, Meldrum BS (July 2000). "Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893)". Neuropharmacology. 39 (9): 1567–74. doi:10.1016/S0028-3908(99)00242-7. PMID 10854901. S2CID 21528282.
- Wang SJ, Sihra TS (June 2004). "Noncompetitive metabotropic glutamate5 receptor antagonist (E)-2-methyl-6-styryl-pyridine (SIB1893) depresses glutamate release through inhibition of voltage-dependent Ca2+ entry in rat cerebrocortical nerve terminals (synaptosomes)". The Journal of Pharmacology and Experimental Therapeutics. 309 (3): 951–8. doi:10.1124/jpet.103.064881. PMID 14982967. S2CID 800526.
- Mathiesen JM, Svendsen N, Bräuner-Osborne H, Thomsen C, Ramirez MT (March 2003). "Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP". British Journal of Pharmacology. 138 (6): 1026–30. doi:10.1038/sj.bjp.0705159. PMC 1573757. PMID 12684257.
This anticonvulsant-related article is a stub. You can help Misplaced Pages by expanding it. |